Back to the full story5 sources · Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%◆ All Sources
Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
2 regions · 5 outlets · 6 reports — every source grouped by where each outlet is based. Region reflects only headquarters, not the subject of the report.
US
3 articles · 3 outlets
CNBCAug 19, 12:54 PM
Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
MarketWatchAug 19, 12:40 PM
Moderna’s stock doubles on promising cancer-vaccine results
Yahoo FinanceAug 19, 12:28 PM
Stock Market Today: Dow Rises Ahead Of Fed Minutes; Moderna Soars On Cancer Drug News (Live Coverage)
Other
3 articles · 2 outlets
QuartzAug 19, 11:40 AM
Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial
STATAug 19, 10:49 AM
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
STATAug 19, 10:45 AM
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial